KT33A Antibody Cat

Total Page：16

File Type：pdf, Size：1020Kb

KT33A Antibody Cat. No.: 55-790 KT33A Antibody Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Mouse HOMOLOGY: Predicted species reactivity based on immunogen sequence: Human This KT33A antibody is generated from rabbits immunized with a KLH conjugated IMMUNOGEN: synthetic peptide between 56-85 amino acids from the N-terminal region of human KT33A. TESTED APPLICATIONS: WB APPLICATIONS: For WB starting dilution is: 1:1000 PREDICTED MOLECULAR 46 kDa WEIGHT: Properties This antibody is purified through a protein A column, followed by peptide affinity PURIFICATION: purification. CLONALITY: Polyclonal ISOTYPE: Rabbit Ig October 1, 2021 1 https://www.prosci-inc.com/kt33a-antibody-55-790.html CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: KRT33A Keratin, type I cuticular Ha3-I, Hair keratin, type I Ha3-I, Keratin-33A, K33A, KRT33A, HHA3- ALTERNATE NAMES: I, HKA3A, KRTHA3A ACCESSION NO.: O76009 GENE ID: 3883 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References The protein encoded by this gene is a member of the keratin gene family. It is one of the type I hair keratin genes which are clustered in a region of chromosome 17q12-q21 and have the same direction of transcription. As a type I hair keratin, it is an acidic protein BACKGROUND: which heterodimerizes with type II keratins to form hair and nails. There are two isoforms of this protein, encoded by two separate genes, KRTHA3A and KRTHA3B. [provided by RefSeq]. REFERENCES: 1) Ewing, R.M., et al. Mol. Syst. Biol. 3, 89 (2007) : 2) Schweizer, J., et al. J. Cell Biol. 174(2):169-174(2006) 3) Rogers, M.A., et al. Differentiation 72 (9-10), 527-540 (2004) : 4) Langbein, L., et al. J. Biol. Chem. 274(28):19874-19884(1999) ANTIBODIES FOR RESEARCH USE ONLY. For additional information, visit ProSci's Terms & Conditions Page. October 1, 2021 2 https://www.prosci-inc.com/kt33a-antibody-55-790.html.

Copy Link

Recommended publications

Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
[Show full text]
Suppl 1.1 All Data Dimethyl Labled
Fasta headers Protein names Gene names Uniprot Ratio H/L normalized exp01 Ratio H/L normalized exp02 Ratio H/L normalized exp03 Ratio H/L normalized exp04 Ratio H/L normalized exp05 Ratio H/L normalized exp06 Ratio H/L normalized exp07 Ratio H/L normalized exp08 Ratio H/L normalized exp09 Ratio H/L normalized exp10 Ratio H/L normalized exp11b Ratio H/L normalized exp12b Peptides exp01 Peptides exp02 Peptides exp03 Peptides exp04 Peptides exp05 Peptides exp06 Peptides exp07 Peptides exp08 Peptides exp09 Peptides exp10 Peptides exp11b Peptides exp12b Unique peptides exp01 Unique peptides exp02 Unique peptides exp03 Unique peptides exp04 Unique peptides exp05 Unique peptides exp06 Unique peptides exp07 Unique peptides exp08 >sp|P01876|IGHA1_HUMAN Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2Ig alpha-1 chain C region IGHA1 P01876 1,90 0,62 2,03 12,53 11,35 0,80 1,87 0,60 0,88 1,60 1,33 1,34 7 6 11 8 10 6 8 8 4 3 7 7 3 3 5 4 5 3 4 3 >sp|P02647|APOA1_HUMAN Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1;>tr|F8W696|F8W696_HUMAN Truncated apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1Apolipoprotein A-I;Truncated apolipoprotein A-I APOA1 P02647 1,71 1,13 0,77 1,73 0,89 1,12 0,61 0,84 1,53 1,46 1,16 0,86 17 16 17 18 16 14 13 16 17 13 14 17 17 16 17 18 16 14 13 16 >sp|P01024|CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2Complement C3;Complement C3 beta chain;Complement C3 alpha chain;C3a anaphylatoxin;Acylation stimulating protein;Complement C3b alpha chain;Complement C3c alpha chain fragment 1;Complement C3dg
[Show full text]
Structural and Biochemical Changes Underlying a Keratoderma-Like Phenotype in Mice Lacking Suprabasal AP1 Transcription Factor Function
Citation: Cell Death and Disease (2015) 6, e1647; doi:10.1038/cddis.2015.21 OPEN & 2015 Macmillan Publishers Limited All rights reserved 2041-4889/15 www.nature.com/cddis Structural and biochemical changes underlying a keratoderma-like phenotype in mice lacking suprabasal AP1 transcription factor function EA Rorke*,1, G Adhikary2, CA Young2, RH Rice3, PM Elias4, D Crumrine4, J Meyer4, M Blumenberg5 and RL Eckert2,6,7,8 Epidermal keratinocyte differentiation on the body surface is a carefully choreographed process that leads to assembly of a barrier that is essential for life. Perturbation of keratinocyte differentiation leads to disease. Activator protein 1 (AP1) transcription factors are key controllers of this process. We have shown that inhibiting AP1 transcription factor activity in the suprabasal murine epidermis, by expression of dominant-negative c-jun (TAM67), produces a phenotype type that resembles human keratoderma. However, little is understood regarding the structural and molecular changes that drive this phenotype. In the present study we show that TAM67-positive epidermis displays altered cornified envelope, filaggrin-type keratohyalin granule, keratin filament, desmosome formation and lamellar body secretion leading to reduced barrier integrity. To understand the molecular changes underlying this process, we performed proteomic and RNA array analysis. Proteomic study of the corneocyte cross-linked proteome reveals a reduction in incorporation of cutaneous keratins, filaggrin, filaggrin2, late cornified envelope precursor proteins, hair keratins and hair keratin-associated proteins. This is coupled with increased incorporation of desmosome linker, small proline-rich, S100, transglutaminase and inflammation-associated proteins. Incorporation of most cutaneous keratins (Krt1, Krt5 and Krt10) is reduced, but incorporation of hyperproliferation-associated epidermal keratins (Krt6a, Krt6b and Krt16) is increased.
[Show full text]
Table S1. the Clinicopathological Data of the Laryngeal Cancer Cases Involved in the Primary Tissue Culture
Table S1. The clinicopathological data of the laryngeal cancer cases involved in the primary tissue culture Case Gender Age at Smoking Alcohol Histological type TNM Tumor coding* diagnosis status status staging† differentiation LC01 male 63 Yes Yes Supraglottic squamous cell carcinoma T4N2M0 Moderate LC14 male 73 Yes Yes Supraglottic squamous cell carcinoma T3N2M0 Moderate LC53 male 54 Yes No Supraglottic squamous cell carcinoma T3N2M0 Moderate LC95 male 50 Yes Yes Glottic squmamous cell carcinoma T3N1M0 Poor *LC represents laryngeal cancer. † staged according to Sixth Edition (2002) of the AJCC-UICC TNM Staging System. Table S2. The clinical characteristics of the 149 patients with laryngeal SCC used for ELISA Variable N (%) Variable N(%) Age (years) Disease stage ≤55 58 (38.9) I 33 (22.1) >55 91 (61.1) II 32 (21.5) Median (range) 58 (35-82) III 41 (27.5) IV 41 (27.5) Missing 2 (1.3) Gender T stage* Male 140 (94.0) T1 33 (21.5) Female 9 (6.0) T2 36 (24.2) T3 52 (34.9) T4 26 (17.4) Missing 2 (1.3) Smoking status Lymph node status Ever 124 (83.2) pN0 110 (73.8) Never 11 (7.4) pN+ 37 (24.8) Missing 14 (9.4) Missing 2 (1.3) Alcohol status Tumor differentiation Yes 84 (56.4) well 34 (22.8) No 51(34.2) moderate 78 (52.3) Missing 14 (9.4) poor 24 (16.1) Missing 13 (8.7) Anatomical region Glottis 82 (55.0) Supraglottis 60 (40.3) Subglottis 1 (0.7) Missing 6 (4.0) *staged according to Sixth Edition (2002) of the AJCC-UICC TNM Staging System.
[Show full text]
The Correlation of Keratin Expression with In-Vitro Epithelial Cell Line Differentiation
The correlation of keratin expression with in-vitro epithelial cell line differentiation Deeqo Aden Thesis submitted to the University of London for Degree of Master of Philosophy (MPhil) Supervisors: Professor Ian. C. Mackenzie Professor Farida Fortune Centre for Clinical and Diagnostic Oral Science Barts and The London School of Medicine and Dentistry Queen Mary, University of London 2009 Contents Content pages ……………………………………………………………………......2 Abstract………………………………………………………………………….........6 Acknowledgements and Declaration……………………………………………...…7 List of Figures…………………………………………………………………………8 List of Tables………………………………………………………………………...12 Abbreviations….………………………………………………………………..…...14 Chapter 1: Literature review 16 1.1 Structure and function of the Oral Mucosa……………..…………….…..............17 1.2 Maintenance of the oral cavity...……………………………………….................20 1.2.1 Environmental Factors which damage the Oral Mucosa………. ….…………..21 1.3 Structure and function of the Oral Mucosa ………………...….……….………...21 1.3.1 Skin Barrier Formation………………………………………………….……...22 1.4 Comparison of Oral Mucosa and Skin…………………………………….……...24 1.5 Developmental and Experimental Models used in Oral mucosa and Skin...……..28 1.6 Keratinocytes…………………………………………………….….....................29 1.6.1 Desmosomes…………………………………………….…...............................29 1.6.2 Hemidesmosomes……………………………………….…...............................30 1.6.3 Tight Junctions………………………….……………….…...............................32 1.6.4 Gap Junctions………………………….……………….….................................32
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2016/0289762 A1 KOH Et Al
US 201602897.62A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0289762 A1 KOH et al. (43) Pub. Date: Oct. 6, 2016 (54) METHODS FOR PROFILIING AND Publication Classification QUANTITATING CELL-FREE RNA (51) Int. Cl. (71) Applicant: The Board of Trustees of the Leland CI2O I/68 (2006.01) Stanford Junior University, Palo Alto, (52) U.S. Cl. CA (US) CPC ....... CI2O 1/6883 (2013.01); C12O 2600/112 (2013.01); C12O 2600/118 (2013.01); C12O (72) Inventors: Lian Chye Winston KOH, Stanford, 2600/158 (2013.01) CA (US); Stephen R. QUAKE, Stanford, CA (US); Hei-Mun Christina FAN, Fremont, CA (US); Wenying (57) ABSTRACT PAN, Stanford, CA (US) The invention generally relates to methods for assessing a (21) Appl. No.: 15/034,746 neurological disorder by characterizing circulating nucleic acids in a blood sample. According to certain embodiments, (22) PCT Filed: Nov. 6, 2014 methods for S. a Nial disorder include (86). PCT No.: PCT/US2O14/064355 obtaining RNA present in a blood sample of a patient Suspected of having a neurological disorder, determining a S 371 (c)(1), level of RNA present in the sample that is specific to brain (2) Date: May 5, 2016 tissue, comparing the sample level of RNA to a reference O O level of RNA specific to brain tissue, determining whether a Related U.S. Application Data difference exists between the sample level and the reference (60) Provisional application No. 61/900,927, filed on Nov. level, and indicating a neurological disorder if a difference 6, 2013.
[Show full text]
Comparative Genomics Suggests Loss of Keratin K24 in Three Evolutionary
www.nature.com/scientificreports OPEN Comparative genomics suggests loss of keratin K24 in three evolutionary lineages of mammals Received: 26 March 2019 Florian Ehrlich1, Maria Laggner2,5, Lutz Langbein3, Pamela Burger 4, Andreas Pollreisz2, Accepted: 16 July 2019 Erwin Tschachler1 & Leopold Eckhart 1 Published: xx xx xxxx Keratins are the main cytoskeletal proteins of epithelial cells and changes in the expression of keratins have contributed to the evolutionary adaptation of epithelia to diferent environments. Keratin K24 was proposed to be a diferentiation marker of epidermal keratinocytes but the signifcance of K24 expression in the epidermis versus other tissues has remained elusive. Here, we show by RT-PCR, western blot, and immunofuorescence analyses that K24 is highly expressed in the epithelium of the cornea whereas its expression levels are signifcantly lower in other stratifed epithelia including in the epidermis. To investigate the evolutionary history of K24, we screened the genome sequences of vertebrates for orthologs of the human KRT24 gene. The results of this comparative genomics study suggested that KRT24 originated in a common ancestor of amniotes and that it was lost independently in three clades of mammals, i.e. camels, cetaceans, and a subclade of pinnipeds comprising eared seals and the walrus. Together, the results of this study identify K24 as component of the cytoskeleton in the human corneal epithelium and reveal previously unknown diferences of keratin gene content among mammalian species. Keratins are intermediate flament (IF) proteins that form the cytoskeleton of epithelial cells1–4. Human epithe- lia contain 28 type I and 26 type II keratins that have a conserved central α-helical domain but difer in several molecular properties such as the presence or absence of glycine and serine-rich sequences in the amino- and carboxy-terminal domains5.
[Show full text]
Gene with Live-Weight and Wool Characteristics In
158 Sumner et al. – KRT33A and production traits Association of the KRT33A (formerly KRT1.2) gene with live-weight and wool characteristics in yearling Perendale sheep RMW Sumnerab*, RHJ Forrestc, H Zhoud, HV Hendersona and JGH Hickfordd aAgResearch Ruakura, Private Bag 3123, Hamilton 3240, New Zealand; bRetired; cFaculty of Sport and Health Sciences, Eastern Institute of Technology, Private Bag 1201, Napier 4142, New Zealand; dFaculty of Agriculture and Life Sciences, PO Box 85084, Lincoln University, Canterbury 7647, New Zealand *Corresponding author. Email: [email protected] Abstract DNA samples from 691 mixed-sex Perendale sheep, born between 1998 and 2001, were typed for variation in the KRT33A gene using polymerase chain reaction - single-strand conformational polymorphism. The sheep were the progeny of two lines selected for either decreased (L), or increased (H) core bulk at yearling shearing, crosses between the lines and back-crosses. Five variants (A–E) of KRT33A were identified with a frequency of 0.07, 0.04, 0.07, 0.35 and 0.47, respectively. The proportion of A decreased and B increased, with a progressive increase in crimp frequency, fibre curvature and core bulk and a progressive decrease in fleece weight, staple length and washing yield with each step-wise increase in the proportion of genes derived from the H line. An effect of the presence of A on the measured wool characteristics was found, but was less than the effect with direct selection for core bulk. There was no consistent effect on body growth. While none of the variants of KRT33A were strongly predictive of variation in core bulk, other genes on Chromosome 11 may be implicated in the differential expression of characteristics associated with core bulk.
[Show full text]
Transcriptome Profiling and Differential Gene Expression In
G C A T T A C G G C A T genes Article Transcriptome Profiling and Differential Gene Expression in Canine Microdissected Anagen and Telogen Hair Follicles and Interfollicular Epidermis Dominique J. Wiener 1,* ,Kátia R. Groch 1 , Magdalena A.T. Brunner 2,3, Tosso Leeb 2,3 , Vidhya Jagannathan 2 and Monika M. Welle 3,4 1 Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Science, Texas A&M University, College Station, TX 77843, USA; [email protected] 2 Institute of Genetics, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland; [email protected] (M.A.T.B.); [email protected] (T.L.); [email protected] (V.J.) 3 Dermfocus, Vetsuisse Faculty, University Hospital of Bern, 3010 Bern, Switzerland; [email protected] 4 Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland * Correspondence: [email protected]; Tel.: +1-979-862-1568 Received: 30 June 2020; Accepted: 3 August 2020; Published: 4 August 2020 Abstract: The transcriptome profile and differential gene expression in telogen and late anagen microdissected hair follicles and the interfollicular epidermis of healthy dogs was investigated by using RNAseq. The genes with the highest expression levels in each group were identified and genes known from studies in other species to be associated with structure and function of hair follicles and epidermis were evaluated. Transcriptome profiling revealed that late anagen follicles expressed mainly keratins and telogen follicles expressed GSN and KRT15. The interfollicular epidermis expressed predominately genes encoding for proteins associated with differentiation. All sample groups express genes encoding for proteins involved in cellular growth and signal transduction.
[Show full text]
Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
[Show full text]
Supplementary Table 5. Pooled Analysis of Global Gene Expression
Supplementary Table 5. Pooled analysis of global gene expression: Downregulated genes Criteria: 1) Signal-to-Noise ratio < -1.4 2) Fold Change < 0.5 (2 fold decrease after IPI-504 treatment) Down-regulated genes (101) NAME DESCRIPTION FC (Rx/NoRx) S2N P-value 1 ABCB8 ABCB8:ATP-binding cassette, sub-family B (MDR/TAP), member 8 0.09 -1.48 0.023 2 ACD ACD:adrenocortical dysplasia homolog (mouse) 0.40 -1.46 0.006 3 ACTB ACTB:actin, beta 0.31 -1.66 0.016 4 ADAM2 ADAM2:ADAM metallopeptidase domain 2 (fertilin beta) 0.35 -1.50 0.017 5 ADAMTS13 ADAMTS13:ADAM metallopeptidase with thrombospondin type 1 motif, 13 0.45 -1.41 0.018 6 ANKRD52 ANKRD52:ankyrin repeat domain 52 0.35 -1.52 0.009 7 AP4B1 AP4B1:adaptor-related protein complex 4, beta 1 subunit 0.46 -1.65 0.009 8 APLN APLN:apelin, AGTRL1 ligand 0.26 -1.74 0.016 9 ARHGEF10L ARHGEF10L:Rho guanine nucleotide exchange factor (GEF) 10-like 0.49 -1.49 0.012 10 ATP13A5 ATP13A5:ATPase type 13A5 0.30 -1.52 0.023 11 AURKB AURKB:aurora kinase B 0.35 -1.53 0.015 12 BCAR1 BCAR1:breast cancer anti-estrogen resistance 1 0.48 -1.80 0.011 13 BLOC1S1 BLOC1S1:biogenesis of lysosome-related organelles complex-1, subunit 1 0.34 -1.41 0.023 14 BTBD14B BTBD14B:BTB (POZ) domain containing 14B 0.41 -1.75 0.010 15 CAMK2A CAMK2A:calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha 0.43 -1.53 0.019 16 CCDC70 CCDC70:coiled-coil domain containing 70 0.13 -1.80 0.006 17 CDC14C CDC14C:CDC14 cell division cycle 14 homolog C (S.
[Show full text]
WO 2014/089124 Al 12 June 20 14 ( 12.06.20 14) W P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/089124 Al 12 June 20 14 ( 12.06.20 14) W P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 48/00 (2006.01) A61P 37/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 39/395 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2013/072938 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 3 December 2013 (03.12.2013) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/732,746 3 December 2012 (03. 12.2012) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/747,653 31 December 2012 (3 1. 12.2012) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, LV, (71) Applicants: CENEXYS, INC.
[Show full text]